Tin tức & Cập nhật

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.

Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.

The risk of psoriasis is elevated in patients with continuous metabolic syndrome (MetS) and in those with newly developed MetS, a recent study has found. In contrast, such risk is absent in individuals with only a history of MetS.